Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials

Source : https://apm.amegroups.com/article/view/61988/html

Lung cancer remains the leading cause of death among cancer patients worldwide, and approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) ( 1). A series of clinical trials have demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are associated with a higher tumor response rate, longer progression-free survival (PFS), and better quality of life compared to conventional chemotherapy.